Home | Investor Relations
Stock Quote (NASDAQ: NSTG)
+ 0.15
Day High:
Day Low:
4:00 PM ET on Feb 12, 2016
Delayed at least 20 minutes.
Provided by eSignal.

Search Investor Relations

Investor Relations

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology has now been applied to diagnostic use. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer.

View all »Upcoming Events

WEBCASTFeb 29, 2016 at 4:30 PM ET
Nanostring 2015 Fourth Quarter Financial Results

View all »Events & Webcasts

WEBCASTFeb 10, 2016 at 1:50 PM ET
The LEERINK Partners 5th Annual Global Healthcare Conference
WEBCASTJan 13, 2016 at 7:30 AM PT
J.P. Morgan 34th Annual Healthcare Conference
PDF View Presentation   3.1 MB   Add to Briefcase
WEBCASTNov 19, 2015 at 1:30 PM ET
Canaccord Genuity 2015 Medical Technology and Diagnostics Forum